Publications by authors named "Margaux Lelong"
Article Synopsis
- Patients with inflammatory bowel disease (IBD) treated with infliximab or vedolizumab showed a COVID-19 prevalence similar to the general French population before vaccinations, with only 4.5% confirmed cases.
- Factors increasing COVID-19 risk included using public transport and living in urban settings, while treatment type or disease activity did not affect infection rates.
- Recommendations suggest that maintaining sanitary barrier measures is essential for IBD patients on biological therapies to minimize the risk of SARS-CoV-2 infection.
This 38-year-old man has a familial BRCA2 mutation. He presented with skin erythema, polyarthritis, dactylitis, and febrile erythema nodosum; a biopsy of a liver metastase revealed acinar cell carcinoma of the pancreas. After FOLFIRINOX, olaparib was initiated, and 24 months after, the patient was PS 0 and asymptomatic.
View Article and Find Full Text PDF